Dariohealth Corp Stock Price, News & Analysis

DarioHealth (Nasdaq: DRIO), a leader in the global digital health market, has announced it will release its Q1 2025 financial results on Wednesday, May 14th, 2025, before market opens. The company will host a conference call and webcast at 8:30 a.m. Eastern Time, featuring CEO Erez Raphael and CCO Steven Nelson.

Participants can join via dial-in numbers (1-800-717-1738 domestic or 1-646-307-1865 international), through the Call me™ link, or via webcast. A replay will be available until May 28th, 2025, using passcode 1118523.

DarioHealth (NASDAQ: DRIO) has secured a strategic debt refinancing facility of up to $50 million from Rand Capital and Callodine Group. The company received $32.5 million at closing, with potential access to an additional $17.5 million based on achieving certain revenue thresholds. The five-year credit agreement matures in April 2030 and includes the issuance of warrants to purchase 2,114,140 shares at $0.8278 per share. Notably, the refinancing defers debt amortization from end of 2025 to 2028, providing DarioHealth with enhanced operational flexibility to execute its B2B2C strategy across pharmaceutical companies, self-insured employers, and payer channels.

DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.

Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.

Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.

DarioHealth (Nasdaq: DRIO) has announced a strategic partnership with a leading national benefit administrator to provide its cardiometabolic solution, including a GLP-1 support program and AI-driven digital health suite to employers. The partnership, which began contributing to revenue in January 2025, addresses rising healthcare costs associated with metabolic conditions.

The collaboration targets the GLP-1 market, projected to reach $100 billion by 2030, and the cardiometabolic disease market, expected to exceed $1.2 trillion by 2033. Dario's comprehensive approach addresses the challenge of GLP-1 medication discontinuation through personalized coaching, AI-driven monitoring, and behavior change strategies.

This partnership marks Dario's first national benefit administrator collaboration, enabling faster employer onboarding and immediate impact on B2B2C recurring revenues for 2025. The agreement serves as a foundational entry into a priority growth segment and provides a reference model for expansion across other national administrators and payer channels.

DarioHealth (NASDAQ: DRIO) has secured a partnership with a major U.S. healthcare research and medical institution, marking its second significant healthcare employer agreement. The partnership, which is already generating recurring revenue in 2025, involves the implementation of Dario's complete suite of AI-powered digital health solutions.

The institution will deploy Dario Health, Dario Mind, and Dario Move platforms, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company's solutions have demonstrated above-average engagement rates and significant improvements in health metrics, including reductions in A1c, blood pressure, and MSK-related pain.

DarioHealth (DRIO) reported strong financial results for Q4 and full-year 2024, with annual revenue increasing 32.9% to $27.0 million. The company's B2B2C channel showed remarkable growth, with recurring revenues rising 300% year-over-year. Q4 2024 revenue reached $7.6 million, up 110% from Q4 2023.

Key highlights include completion of a $25.6 million equity financing, resulting in a $34.5 million proforma cash balance. Operating loss decreased by 35% to $11.7 million (GAAP) in Q4 2024. The company added 36 new employer and health plan clients in 2024, bringing total client base to 83, with a projected 50% net client growth in 2025.

Following the Twill acquisition, Dario expanded its AI-powered platform to support five chronic conditions. The company expects to achieve operational cash flow breakeven by end of 2025, supported by an anticipated 20% reduction in operating expenses. Gross margins exceeded 80% in the B2B2C business over the past three quarters.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic collaboration with Rula Health to expand its behavioral health offerings through access to over 15,000 providers nationwide. The partnership aims to enhance Dario's B2B2C sales growth by integrating Rula's extensive provider network, which covers over 120 million commercial lives through major insurance networks.

The collaboration creates an 'easy button' solution for employers implementing behavioral health support within existing benefits structures. The integrated solution combines Dario's digital health capabilities, including AI-driven engagement and digital coaching, with Rula's provider network to deliver comprehensive mental health support.

This strategic arrangement is expected to accelerate Dario's presence in the employer channel while increasing visibility through Rula's partner base. The partnership focuses on delivering personalized, evidence-based behavioral health support and seamless access to licensed therapists.

DarioHealth Corp. (NASDAQ: DRIO) has secured a significant contract with a major healthcare system, marking its entry into the healthcare provider employer market in Q1 2025. This agreement contributes to Dario's 15 new client signings targeted for 2025.

The partnership will provide AI-powered chronic care management solutions to the healthcare system's employees, focusing on conditions including diabetes, hypertension, musculoskeletal pain, and mental health. Clinical studies demonstrate Dario's effectiveness, showing a 2.3-point reduction in A1C levels for diabetes patients and 28-30% decrease in anxiety and depression over eight weeks through its Dario Mind platform.

This milestone represents a breakthrough in healthcare system adoption of digital health solutions, traditionally a slower-moving sector due to reimbursement challenges and provider skepticism. The partnership validates Dario's approach to combining AI-driven personalization with user-friendly interfaces to bridge the gap between traditional care models and digital interventions.

DarioHealth Corp (Nasdaq: DRIO), a digital health market leader, has scheduled its Q4 and full-year 2024 financial results announcement for Monday, March 10th, 2025, before market opening. The company will host a conference call and webcast at 8:30 AM ET, featuring CEO Erez Raphael and CCO Steven Nelson.

Participants can join via phone using domestic (1-800-717-1738) or international (1-646-307-1865) dial-in numbers, or through the Call me™ link available 15 minutes before the event. A webcast option is also available. The earnings call replay will be accessible until March 24th, 2025, using replay passcode 1134608.